Skip to main content

Table 6 Demographic and clinical characteristics for the different genotypes of rs10733113 in UC patients

From: Genotype–phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients

 

rs10733113

GG

rs10733113

AG

rs10733113

AA

p value (Fisher or Kruskal–Wallis)

Gender

 Male (n = 369)

 Female (n = 321)

276 (53.5%)

240 (46.5%)

10 (71.4%)

4 (28.6%)

83 (51.9%)

77 (48.1%)

0.392

Age at diagnosis [years]

 Median, q25q75,

 Minmax

27.7, 19.8–38.7,

2.9–79.6

38.0, 27.1–40.8,

19.5–63.2

29.2, 19.7–36.7,

3.4–69.4

0.099

Disease duration [years]

 Median, q25q75,

 Minmax

11.1, 6.7–18.4,

0.2–49.5

10.7, 7.8–17.8,

2.9–26.3

11.7, 7.3–18.8,

0.5–40.1

0.619

Complications*

 No (n = 286)

 Yes (n = 404)

225 (43.6%)

291 (56.4%)

6 (42.9%)

8 (57.1%)

55 (34.4%)

105 (65.6%)

0.122

MTWAI–maximal value throughout follow-up

 Median, q25q75,

 Minmax

4, 2–8.5,

0–19

7.5, 3–9,

0–13

5, 2–9,

0–17

0.704

Reported flare*

 No (n = 284)

 Yes (n = 406)

213 (41.3%)

303 (58.7%)

7 (50.0%)

7 (50.0%)

64 (40.0%)

96 (60.0%)

0.753

Flare possibly or highly related to (focus on yes):

 NSAIDs

 Antibiotics

 GI tract infection

 Other infection

 Treatment decr. / disc

 Other medication

19 (6.3%)

6 (2.0%)

51 (16.8%)

29 (9.6%)

74 (24.4%)

9 (3.0%)

0 (0%)

1 (14.3%)

1 (14.3%)

0 (0%)

2 (28.6%)

0 (0%)

4 (4.2%)

1 (1.0%)

22 (22.9%)

10 (10.4%)

22 (22.9%)

5 (5.2%)

0.746

0.150

0.347

0.924

0.864

0.484

Flare management (focus on the yes):

 Hospitalization

 Ambulatory

 Surgery

 Drug therapy

39 (12.9%)

89 (29.4%)

16 (5.3%)

271 (89.4%)

0 (0%)

1 (14.3%)

0 (0%)

7 (100%)

7 (7.3%)

14 (14.6%)

3 (3.1%)

90 (93.8%)

0.278

0.008

0.702

0.367

Focus on the hospitalizations:

 Total days of hosp.

 Median, q25q75,

 Minmax

4, 0–16,

0–90

0, 0–3,

0–12

0.063

  1. Bold indicates a significant p-value (p < 0.05)